The breakthrough in lung cancer treatment was the discovery of the role of epithelial growth factor receptor (EGFR) and cytotoxic T cell antigen 4 (CTLA4) in the metabolic pathways of the NSCLC and further application of drugs based on tyrosine kinase inhibitors (TKI). This evidence concerns the gene EGFR and non-small cell lung carcinoma.